BJDX · Bluejay Diagnostics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These financial results and financial position, and the Company's expected forward-looking outlook of significant negative cash flow in the future, raise substantial doubt with respect to its ability to continue as a going concern.”View the 10-Q filed May 7, 2026
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BJDX
this stock
Bluejay Diagnostics, Inc.
|
$1.19M | -59.9% | — | — | 55.1% |
|
ABT
Abbott Laboratories
|
$187.78B | -12.4% | +5.7% | 30.2 | 1.4% |
|
SYK
Stryker Corp
|
$129.43B | -3.0% | +11.2% | 35.0 | 1.8% |
|
MDT
Medtronic plc
|
$109.98B | -7.7% | +8.4% | 23.0 | 1.5% |
|
BSX
Boston Scientific Corp
|
$71.45B | -48.3% | +5.5% | 20.0 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BJDX | +24.4% | -26.2% | -59.9% | +24.4% | -59.9% |
| SPY | +3.5% | +2.4% | +13.4% | +3.5% | +13.4% |
| vs SPY | +20.9% | -28.6% | -73.4% | +20.9% | -73.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.